PMID- 36258236
OWN - NLM
STAT- MEDLINE
DCOM- 20221020
LR  - 20221207
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 23
IP  - 1
DP  - 2022 Oct 18
TI  - Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes 
      mellitus patients in China.
PG  - 79
LID - 10.1186/s40360-022-00621-2 [doi]
LID - 79
AB  - BACKGROUND: Acarbose is one of the optimal drugs for patients with the first 
      diagnosis of type 2 diabetes mellitus (T2DM). But what kind of emerging patients 
      has the best therapeutic response to acarbose therapy has never been reported. To 
      this end, we investigated predictors of acarbose therapeutic efficacy in newly 
      diagnosed T2DM patients in China. METHODS: A total of 346 T2DM patients received 
      acarbose monotherapy for 48 weeks as part of participating in the Study of 
      Acarbose in Newly Diagnosed Patients with T2DM in China (MARCH study) from 
      November 2008 to June 2011. Change in glycated hemoglobin (DeltaHbA1c) served as a 
      dependent variable while different baseline variables including sex, age, disease 
      duration, weight, body mass index (BMI), systolic blood pressure (SBP), diastolic 
      blood pressure (DBP), HbA1c, fasting plasma glucose (FPG), 2-h postprandial blood 
      glucose (2 h PG), fasting insulin (FINS), 2-h postprandial insulin (2 h INS), 
      early insulin secretion index (IGI), homeostasis model assessment of insulin 
      resistance index (HOMA-IR), homeostasis model assessment of beta cell function 
      (HOMA-B), area under the curve (AUC) of glucagon, insulin and GLP-1 were assessed 
      as independent predictors. Step-wise multiple linear regression was employed for 
      statistical analysis. RESULTS: The results suggested that independent predictors 
      of DeltaHbA1c at 12 weeks included baseline body weight (beta = - 0.012, P = 0.006), DBP 
      (beta = 0.010, P = 0.047), FPG (beta = 0.111, P = 0.005) and 2 h PG (beta = 0.042, 
      P = 0.043). Independent predictors of DeltaHbA1c at 24 weeks included disease 
      duration (beta = 0.040, P = 0.019) and FPG (beta = 0.117, P = 0.001). Finally, 
      independent predictor of DeltaHbA1c at 48 weeks was disease duration (beta = 0.038, 
      P = 0.046). CONCLUSIONS: Acarbose may be more effective in newly diagnosed T2DM 
      patients with low FPG, low 2 h PG and obesity. The earlier T2DM is diagnosed and 
      continuously treated with acarbose, the better the response to therapy.
CI  - (c) 2022. The Author(s).
FAU - Zhang, Rong
AU  - Zhang R
AD  - Department of Geriatrics, Xijing Hospital of Air Force Medical University, No.127 
      West Changle Road, Xi'an, 710032, China.
FAU - Zhao, Quanxi
AU  - Zhao Q
AD  - Department of Pharmacy, Second People's Hospital of Shaanxi Province, No.3 
      Shangqin Road, Xi'an, 710068, China.
FAU - Li, Rong
AU  - Li R
AD  - Department of Geriatrics, Xijing Hospital of Air Force Medical University, No.127 
      West Changle Road, Xi'an, 710032, China. wwqlrrs@fmmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221018
PL  - England
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
RN  - T58MSI464G (Acarbose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Blood Glucose)
RN  - 9007-92-5 (Glucagon)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Insulins)
RN  - 0 (Insulin)
SB  - IM
MH  - Humans
MH  - Acarbose/therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Blood Glucose/analysis
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Glucagon/therapeutic use
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - China
MH  - *Insulins/therapeutic use
MH  - Insulin/therapeutic use
MH  - *Insulin Resistance
PMC - PMC9580108
OTO - NOTNLM
OT  - Acarbose
OT  - Newly diagnosed type 2 diabetes mellitus
OT  - Predictors
OT  - Therapeutic efficacy
COIS- The authors declare that they have no competing interests.
EDAT- 2022/10/19 06:00
MHDA- 2022/10/21 06:00
PMCR- 2022/10/18
CRDT- 2022/10/18 23:41
PHST- 2022/04/05 00:00 [received]
PHST- 2022/10/10 00:00 [accepted]
PHST- 2022/10/18 23:41 [entrez]
PHST- 2022/10/19 06:00 [pubmed]
PHST- 2022/10/21 06:00 [medline]
PHST- 2022/10/18 00:00 [pmc-release]
AID - 10.1186/s40360-022-00621-2 [pii]
AID - 621 [pii]
AID - 10.1186/s40360-022-00621-2 [doi]
PST - epublish
SO  - BMC Pharmacol Toxicol. 2022 Oct 18;23(1):79. doi: 10.1186/s40360-022-00621-2.